Robert Booth, PhD
Since 2010, Robert Booth, PhD, has been the Chief Executive Officer of Virobay, Inc., a drug discovery and development company. Dr. Booth was the Founder of Virobay and served as its Executive Chairman from 2006 to 2010 and served concurrently as an Operating Partner and Senior Advisor at TPG Biotech, a venture capital company. Dr. Booth is also the Executive Chairman and co-founder of Ab Initio Biotherapeutics.
From 2002 to 2006, Dr. Booth was the Chief Scientific Officer at Celera Genomics, where he was responsible for leading all discovery and development activities. Dr. Booth conceived and initiated the Btk tyrosine kinase inhibitor program that was licensed to Pharmacyclics and from which Imbruvica was discovered and developed. Dr. Booth served on the board of directors of Pharmacyclics until its acquisition by Abbvie for $21 billion in 2015.
Dr. Booth was at Roche from 1989 to 2002, in positions of increasing responsibility and was the Senior Vice President and Business Unit Leader for Roche in Palo Alto, California. Dr. Booth was a member of the Global Research Management Team and a member of the Business Development Committee, which oversaw licensing opportunities for Roche.
During his time at Roche, Dr. Booth managed R&D organizations in both the US and Europe. The Biology team for which Dr. Booth was responsible in the UK discovered and contributed to the development of saquinavir, the first HIV protease inhibitor to be launched. Roche was recognized for the discovery and development of saquinavir by the winning of the Prix Galien.
Dr Booth currently serves as a member of the board of directors of Galleon Pharmaceuticals, Glialogix, Inc. and Ab Initio Biotherapeutics, in addition to that of Virobay, Inc.. Dr Booth is also a member of the Scientific Advisory Boards of Galleon Pharmaceuticals and Elcelyx. Dr. Booth also served on the board of directors of Pharmacycics Inc. until its acquisition by Abbvie in 2015.
Dr. Booth is a Consulting Professor in the School of Medicine at Stanford University and also serves as an advisor to the Stanford SPARK program. He has approximately 50 published scientific articles and is an inventor on 9 patents
Dr. Booth received his Ph.D. and B.Sc. from the University of London in the field of biochemistry.